RP-HPLC method was developed for the determination of Omeprazole (OME) & Aspirin (ASP) in bulk and dosage form. Mobile phase use for the separation of OME & ASP is methanol and 0.05%OPA in water (pH= 3.5) with ratio of 60:40. The Colum used as C 18 (Cosmosil) 4.6×150mm and flow rate 0.7mL/min. UV detector is used and the detection wavelength is 231nm. Retention time of OME and ASP are 4.61 & 8.03 min, respectively. This method was validated as per ICH guidelines. Linearity was observed at 10-50µg/mL of OME and 20-100µg/mL of ASP. The % RSD is found to be less than 2%.The resolution between OME and ASP is 11.55 and the tailing factors of both are less than 2.0.Therotical plates for OME and ASP are 5060, and 9367, respectively. Total run time is 15min. The developed RP-HPLC method was accurate, precise, selective and rapid for simultaneous estimation of Omeprazole and Aspirin in the pharmaceutical dosage form." 
INTRODUCTION
YOSPRALA is a combination of aspirin, an anti-platelet agent, and omeprazole, a proton pump inhibitor (PPI), indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers.
Reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli,
• Reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris,
• Reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris,
• Use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA] ) when there is a pre-existing condition for which aspirin is already indicated.
The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin associated gastric ulcers in patients at risk for developing aspirinassociated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers.
The aim of the present work was to develop simple, economic, accurate, specific and precise RP-HPLC
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[323] CODEN (USA): JDDTAO methods for simultaneous estimation of omeprazole and aspirin in bulk drugs and combined pharmaceutical formulation and validation of newly developed analytical method.
Omeprazole is use proton pump inhibitor (Antacid), chemically (4-methoxy-3,5-dimethylpyridyl,5-methoxybbenzimidazol.Litreature survey of omeprazole has been estimated by UV, HPLC, HPTLC, RP-HPLC. 
Determination of wavelength maxima 5, 6
Both the standard solution was scanned between 400nm to 200nm.The overlain spectrum of both drugs was recorded. From the overlain spectrum, 297nm (λmax of omeprazole) and 222 nm (λmax of Aspirin) were selected for estimation of drugs and the isobestic point was found to be at 231 nm and it is shown in fig 3 -UV of Aspirin -UV of Omeprazole 
Selection of chromatographic mode
Proper selection of the method depend upon the nature of the sample (ionic, ionisable and neutral, its molecular weight and solubility. Both the drugs are freely soluble in organic. Hence, reversed phase HPLC was selected for the initial separations because of its simplicity and suitability.
Selection of Mobile phase
Omeprazole and Aspirin are freely soluble in HPLC grade of methanol. Not freely soluble in orthophosphoric acid and used uitrasonication. Both drugs are soluble in methanol and orthophosphoric acid. 
Mobile Phase

RESULT AND DISCUSSION
Orthophosparic acid water -0.1mL OPA in 200mL water. (0.05%)
Preparation of stock solution
Accurately weighed of Omeprazole 10mg and 20mg Aspirin was taken in 10mL volumetric flask and dissolved in 10 mL methanol. To get standard stock solution.1000 µg/mL Omeprazole and 2000 µg/mL Aspirin. STOCK -I
Preparation of mobile phase
Pipette out 60 ml of concentrated methanol and 40 ml of 0.05% OPA make up the volume up to 100ml and Sonicate 5 min.
1) Take 0.1mL from the stock I and make up the volume with mobile Phase 10 mL = 10 µg/mL Omeprazole and 20 µg/mL Aspirin.
2) Take 0.2 mL from the stock I and make up the volume with mobile Phase 10 mL = 20 µg/mL Omeprazole and 40 µg/mL Aspirin.
3) Take 0.3 mL from the stock I and make up the volume with mobile Phase 10 mL = 30 µg/mL Omeprazole and 60 gm/mL Aspirin. 4) Take 0.4 mL from the stock I and make up the volume with mobile Phase 10 mL = 40 µg/mL Omeprazole and 80 µg/mL Aspirin. 5) Take 0.5 mL from the stock I and make up the volume with mobile Phase 10 mL = 50 µg/mL Omeprazole and 100 µg/mL Aspirin. Brand Name: Yosprala
Weigh and finely powder 20 tablets. Accurately weigh and transfer a quantity of powder sample equivalent to 10mg of Omeprazole and 20mg of Aspirin into a 10 ml clean dry volumetric flask, add 10ml methanol and sonicate to dissolve it completely and make volume up to the mark with the diluents(1000 µg/mL Ome and 2000 µg/mL. From these solutions 0.1ml was pipette out and transferred into 10ml volumetric flask and makeup the volume up to the mark with methanol & Orthophosphoric acid (10 µg/mL Omeprazole and 20 µg/mL Aspirin) and measured the absorbance at 231nm. The % purity of the drug was calculated by comparing the absorbance of test solution with standard. Linearity:-The con. of ome and asp solution take in different concentration respect.10-50ug/mL, 20-100ug/mL. At selected wavelength 231nm. Precision:-The precision intraday and inter day Precision system result showed good reproducibility. Intraday precision study was carried out by preparing drug solution from stock solution, aliquots of Omeprazole and Aspirin 0.2, 0.3, 0.4 ml were taken an diluted to 10 ml with diluents such that the final concentration of Ome-20, 30, 40 µgm/mL and Asp-40, 60, 80 µg/mL and analyzed. The same procedure was followed for second day also to determine inter-day precision. The recovery of an analytical method is determined by applying the method to analyzed samples to which known amounts of analyte have been added. The Recovery is calculated from the test results as the percentage of analyte recovered by the assay. Three replicate injections, each of three different test concentrations in the range of 80%, 100% and 120% of labeled claim of tablet under study yielded the result within 98 to 102% of true concentration of each drug. The results indicated that the method is accurate. The robustness of an analytical method is a measure of its capacity to remain unaffected by small but deliberate variations in method parameters and provides an indication of its reliability during normal usage. To verify the robustness of the method, the analysis was done under variables flow rate, mobile phase ratio and wavelength.
Tab
System suitability parameter
The system was evaluated by analyzing repeatability, retention time, tailing factor and theoretical plats of the column. 
Limit of Detection (LOD)
The LOD is the lowest limit that can be detected. Based on the S.D. of the response and the slope. The limit of detection (LOD) may be expressed as: The LOD of Omeprazole and Aspirin was found to be 0.5946 (µg/ml) and 0.5375 (µg/ml) respectively.
Limit of Quantitation
The LOQ is the lowest concentration that can be quantitatively measured. Based on the S.D. deviation of the response and the slope. (µg/ml (Aspirin)
The LOQ of Omeprazole and Aspirin was found to be 1.9820 (µg/mL) and 1.6290 (µg/mL) respectively. 
Summary of validation parameter
